Tariff-related Litigation Update – 6/27

WASHINGTON—AdvaMed, the medtech association, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally. 

AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more

Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy

WASHINGTON—AdvaMed, the medtech association, today submitted formal comments responding to the U.S. Department of Commerce investigation into whether the U.S.’s current level of medtech imports has national security implications. The comments outlined medtech as an American success story and the United States as the global leader in innovating and making the highest quality medtech for the United States and world, an export powerhouse, and much less reliant on medtech imports than sometimes perceived.

WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into whether the U.S.’s current level of medtech imports has national security implications:

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.